Macro Group Pharmaceutical S.A.E. (Macro Capital) is specialized in developing, manufacturing and marketing pharmaceuticals. The company's products include anti-scar, skincare, antiseptic, hair care, oral care and muscle relaxant medicines. In addition, the group offers plant-based medicines. At the end of 2021, Macro Group Pharmaceutical S.A.E. (Macro Capital) had one production site in Egypt.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
22/06/26	1.230 £	-0.81%	13,274,780
21/06/26	1.240 £	0.00%	17,617,136
17/06/26	1.240 £	0.00%	40,957,420
16/06/26	1.240 £	0.00%	37,499,670
15/06/26	1.240 £	0.00%	14,805,780

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Egyptian Exchange Other stock markets 22/06/2026			5-day change	1st Jan Change
1.230 ^EGP	-0.81%		-0.81%	+7.89%

05-17	Macro Group Pharmaceutical Q1 consol profit egp 33.3 million	RE
02-20	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	701M 14.09M 12.31M 11.39M 10.63M 19.96M 1.33B 20.1M 135M 52.66M 655M 52.91M 51.76M 2.27B	P/E 2024	-33.1x	P/E 2025	5.7x
Enterprise Value	859M 17.25M 15.08M 13.95M 13.02M 24.44M 1.63B 24.61M 166M 64.48M 802M 64.78M 63.37M 2.78B	EV / Sales 2024	3.03x	EV / Sales 2025	0.9x
Free-Float	95.08%	Yield 2024 *	-	Yield 2025	-

05-17	Macro Group Pharmaceutical Q1 consol profit egp 33.3 million	RE
02-20	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-19	Macro Group Pharmaceutical FY consol profit EGP 115.7 mln	RE
11-19	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	Macro Group Pharmaceutical nine-month consol loss EGP 66.1 million	RE
12/10/25	Macro Group Pharmaceutical shareholders approve authorized capital increase to EGP 3 billion	RE
21/08/25	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
21/08/25	Macro Group Pharmaceutical posts Q2 consol profit EGP 46.5 mln	RE
21/08/25	Macro Group Pharmaceutical board approves renewal of EGP 100 mln short-term financing from KFH	RE
22/07/25	Macro Group Pharmaceutical board proposes capital increase	RE
10/06/25	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
10/04/25	MACRO Group Pharmaceutical's 328.6 Million Shares Block Traded For EGP 631 Million - EGX	RE
27/02/25	Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI

1 day	-0.81%
1 week	-0.81%
Current month	-1.60%
1 month	+0.82%
3 months	-9.56%
6 months	+9.82%
Current year	+7.89%

Macro Group Pharmaceuticals (Macro Capital) S.A.E Stock

Stocks

MCRO

EGS7D971C011

Pharmaceuticals

Valuation: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Chart: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Latest news : Macro Group Pharmaceuticals (Macro Capital) S.A.E

Quotes and Performance

Course Extremes

Managers and Directors: Macro Group Pharmaceuticals (Macro Capital) S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	1.22	1.27
1 month	1.2	1.31
Current year	1.02	1.68
1 year	0.81	4.11
3 years	0.81	4.11
5 years	0.81	5.28
10 years	0.81	5.28

Manager	Title	Age	Since
Khaled Kamel CEO	Chief Executive Officer	-	-
Zeina Shahin IRC	Investor Relations Contact	-	-
Tamer Raouf SAM	Sales & Marketing	-	01/01/2022

Director	Title	Age	Since
Ahmed El-Nayeb CHM	Chairman	-	01/01/2002
Tamir Saeed BRD	Director/Board Member	-	01/01/2021
Norbert Lurz BRD	Director/Board Member	-	01/01/2021

	2024	2025
Net sales	520M 10.45M 9.13M 8.44M 7.88M 14.8M 987M 14.9M 100M 39.04M 485M 39.22M 38.37M 1.69B	895M 17.97M 15.7M 14.53M 13.56M 25.45M 1.7B 25.64M 173M 67.17M 835M 67.48M 66.02M 2.9B
Net income	-38.1M -765K -669K -619K -577K -1.08M -72.34M -1.09M -7.35M -2.86M -35.57M -2.87M -2.81M -124M	116M 2.33M 2.03M 1.88M 1.75M 3.29M 220M 3.32M 22.33M 8.69M 108M 8.73M 8.54M 375M
Net Debt	254M 5.1M 4.46M 4.12M 3.85M 7.23M 482M 7.28M 49.01M 19.07M 237M 19.16M 18.74M 824M	157M 3.16M 2.76M 2.56M 2.39M 4.48M 299M 4.51M 30.37M 11.82M 147M 11.87M 11.62M 510M

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MACRO GROUP PHARMACEUTICALS (MACRO CAPITAL) S.A.E	-0.81%	-0.81%	-38.50%	-58.16%	14.09M
ELI LILLY AND COMPANY	+0.32%	-2.41%	+44.49%	+140.80%	983B
JOHNSON & JOHNSON	+1.27%	-1.85%	+54.41%	+39.65%	557B
ABBVIE INC.	+6.25%	+3.80%	+24.13%	+67.39%	406B
ROCHE HOLDING AG	+1.34%	-1.93%	+23.33%	+16.35%	314B
ASTRAZENECA PLC	+1.29%	+1.31%	+29.16%	+17.83%	273B
NOVARTIS AG	+1.46%	+1.89%	+28.27%	+34.48%	272B
NOVO NORDISK A/S	+0.63%	+8.22%	-32.69%	-44.26%	203B
AMGEN INC.	+2.11%	-1.66%	+19.14%	+50.10%	186B
GILEAD SCIENCES, INC.	+0.90%	+0.46%	+15.09%	+59.86%	155B
Average	+1.46%	-0.91%	+16.68%	+32.40%	335.04B
Weighted average by Cap.	+1.60%	-2.22%	+31.66%	+64.72%